+65 3158 9940
1300 798 820
+64 9801 0299
We take care of your product as if it were our own. We manage the regulatory and reimbursement complexities to ensure our partner’s drugs are commercialised to the highest standards.
Specialised Therapeutics has a strong track record championing partner products from pre-registration through to full commercialisation.
Our regulatory and reimbursement teams bring deep experience navigating complex registration
and reimbursement pathways in Australia, New Zealand and across South East Asia.
Specialised Therapeutics employs highly-skilled pharmaceutical executives with wide industry experience gained at some of the world’s largest pharma companies across numerous speciality therapeutic areas.
We are open to joint ventures, typical licensing agreements or other creative, mutually beneficial partnering opportunities.
Our regulatory team manages complex submission processes in all key markets, including Orphan and Fast-Track designations.
Our commercial team achieves rapid market penetration and leadership of portfolio therapies.
Our experienced teams navigate reimbursement applications and processes for pharmaceutical products, companion diagnostics and other medical technologies.
We successfully launch and manage Named Patient Access Programs in our regions, enabling patients early or compassionate access to new therapies.
We work closely with our global business partners and take care of their products as if they were our own. Ulrich Kosciessa from photonamic GmbH discusses our successful partnership.
We collaborate with international partner companies, championing their speciality products from pre-registration through to full commercialisation
Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and ...
Singapore, 22 October 2021: Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Incyte Biosciences International ...
Singapore, 06 November 2020: A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be available to patients in ...
Singapore, 18 December, 2019: Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an exclusive license deal with ...
This article appeared on page 36 in Pharma Asset Insights (a Scrip industry publication). Click on the Fullscreen ...
SARAH-JANE TASKER | THE AUSTRALIAN| MARCH 19, 2016 12:00AM From Big Pharma to Small Starts: Risking it All ...